Program

POSTER SESSION A-01: Clinical Trials Design and Simulations

Tracks

POSTER AREA (M1 building upper floor)

Monday, July 22, 2024

9:00 AM - 5:00 PM

POSTER AREA (M1 building upper floor)

Presentations

Ms. Danai Andreadi

Associate Specialist Biostatistician

Nestlé, Lausanne, Switzerland

P-A01-01 | Adaptive design implementation as a way to cope with recruitment difficulties

Dr. Shenghua Yuan

Senior Biostatistician

LFB-USA, Framingham MA, United States

P-A01-02 | A practical seamless phase II/III design for special populations and rare disease settings

Dr. Gianmarco Caruso

Research Associate

University of Cambridge, United Kingdom

P-A01-03 | A response-adaptive multi-arm design for normal endpoints using entropy-based allocation rule

Ms. Michaela Maria Freitag

Charité - Universitätsmedizin Berlin, Germany

P-A01-04 | Exploring efficient drug discovery for Major Depressive Disorder: A Phase II platform trial design

Ms. Vanessa Ihl

Rwth Aachen University, Germany

P-A01-05 | Quantification of allocation bias in clinical trials under a response-adaptive randomisation procedure for normal response variables

Dr. Ryota Ishii

University of Tsukuba, Ibaraki, Japan

P-A01-06 | Bias adjustment in an adaptive seamless design with different binary outcomes

Dr. Ayon Mukherjee

IQVIA, Frankfurt am Main, Germany

P-A01-07 | Covariate-adjusted response adaptive designs for semi-parametric survival models

Mr. Rainer Puhr

Monash University, Melbourne, Australia

P-A01-08 | A fast, flexible simulation framework for Bayesian adaptive designs with time-to-event endpoints

Dr. Hong Sun

Bristol-Myers-Squibb, Boudry, Switzerland

P-A01-09 | Speeding up the clinical studies with biomarker-based randomisation or adaptive Bayesian design with biomarker enrichment

Dr. Silvia Calderazzo

German Cancer Research Center (DKFZ), Heidelberg, Germany

P-A01-10 LB | Adaptive quantification of prior impact in terms of effective sample size

Ms. Ajsi Kanapari

Unit of Biostatistics, Epidemiology and Public Health, University of Padua, Italy

P-A01-12| Mind the Gap: A scoping review on Machine Learning and Artificial Intelligence in the design of Clinical Trials

Ms. Ajsi Kanapari

Unit of Biostatistics, Epidemiology and Public Health, University of Padua, Italy

P-A01-13 | Stratified propensity score randomisation: The effect of integrating machine learning in the clinical trial design

Prof. J. Jack Lee

University of Texas MD Anderson Cancer Center, Houston TX, United States

P-A01-14 | Augmenting control arm of randomised-controlled trials by incorporating information across multiple external sources with stratified propensity score and data-driven mixture prior

Ms. Maria Vittoria Chiaruttini

Phd Student

University of Padua, Italy

P-A01-15 | Efficient group sequential design: Harnessing dynamic historical borrowing in medical device trial

Prof. Dimitris Karlis

Athens University of Economics and Business, Greece

P-A01-16 | Single-arm hierarchical testing with historical controls

Ms. Cristina Marelli

Research Fellow

IRCCS Ospedale Policlinico San Martino, Genoa, Italy

P-A01-17 | A 1:1:1 matching design to account for centre-specific prophylaxis/treatment administration in observational studies

Dr. Guido Moreira

Biostatistician

Bavarian-Nordic, Regensburg, Germany

P-A01-18 | Random weights for historical control enrichment

Ms. Giulia Risca

University of Milano-Bicocca, Italy

P-A01-19 | Basket trials in very rare diseases: Are they feasible?

Dr. Anais Andrillon

Saryga, Tournus, France

P-A01-20 | U-DESPA: A utility-based Bayesian approach for dosage optimisation handling PK, PD safety and efficacy in oncology clinical trials

Ms. Weishi Chen

University of Cambridge, United Kingdom

P-A01-21 | An efficient approach to operational prior specification in Phase I dose-combination escalation trials

Ms. Linxi Han

University of Bristol

P-A01-22 | Bayesian hierarchical model for dose-finding trial incorporating historical data

Prof. Dr. Thomas Jaki

University of Regensburg, Germany

P-A01-23 | Joint TITE-CRM: A design for dose finding studies for therapies with late-onset safety and activity outcomes

Mr. Daniel Bodden

Statistican

Rwth Aachen University, Cologne, Germany

P-A01-24 | Allocation bias in group sequential designs

Dr. Shun Fu Lee

McMaster University, Hamilton, Canada

P-A01-25 | Internal pilot sample size re-estimation for the B-free trial - A cluster randomised crossover trial

Ms. Stefanie Schoenen

Rwth Aachen University, Germany

P-A01-27 | Quantifying the impact of allocation bias in randomised clinical trials with multi-component endpoints

Dr. Takashi Sozu

Professor

Tokyo University of Science, Japan

P-A01-28 | Sample size determination considering the functional relationship between co-primary endpoints in clinical trials

Ms. Satomi Okamura

Osaka University Hospital, Japan

P-A01-29 | Non-inferiority trials with evidence of assay sensitivity considering effect modification

Dr. Ulrike Poetschger

St. Anna Kinderkrebsforschung - CCRI, Vienna, Austria

P-A01-30 | Pseudo-value regression for the design of non-inferiority studies in Paediatric Oncology

Ms. Valeria Mazzanti

Associate Director

Cytel Inc., Dallas TX, United States

P-A01-31 | Optimising oncology clinical trial strategies: Comparative analysis of single versus dual endpoint designs

Dr. Chieh Chiang

Tamkang University, New Taipei City, Taiwan

P-A01-32 | The use of two-sided tolerance interval testing with considering the variability of batches in the assessment of biosimilarity

Mr. Ruochen Du

Phd Student

National University of Singapore

P-A01-33 | Estimating treatment effect in randomised controlled trials with continuous outcomes subject to non-compliance via a CACE framework: A logistic regression based multiple imputation approach

Ms. Mizuna Itagaki

Chuo University, Tokyo, Japan

P-A01-34 | Extension the outcome of two stage design to survival time

Mr. Dominic Stringer

Research Fellow (principal Trial Statistician)

Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom

P-A01-36 | Should we use correlation between clinical trial outcomes as we do for a single trial outcome with repeated measures?

Ms. Foteini Tsotra

Athens University of Economics and Business, Greece

P-A01-37 | Selection of time to measure the RMST: A simulation study

Mr. Haotian Wang

University of Warwick, Coventry, United Kingdom

P-A01-38 | A review of methods for optimal utility-based design of oncology clinical development programmes

Ms. Xinyue (Sylvia) Zhang

Newcastle Unversity, Newcastle upon Tyne, United Kingdom

P-A01-39 | Enhancing endpoint analysis in inflammatory bowel disease trials: A comparative study of different modelling strategies

Mr. Boaz Adler

Director, Global Product Engagement